HOXA5 and acute myeloid leukemia: Thus, HOXA5 has been discussed as a differential epigenetic biomarker between malignant and benign biliary tissues [62], while downregulation of the HOXA5 gene by aberrant promoter methylation was described in the vast majority of NSCLCs [31] and shown also for the development and progression of AML [28, 63].